Welcome to our dedicated page for Halozyme Thrp SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Halozyme Therapeutics, Inc. (HALO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company, Halozyme uses Forms 10-K, 10-Q and 8-K to report on its drug delivery business, collaborations, financing activities and governance matters.
Through current reports on Form 8-K, Halozyme discloses material events such as the issuance of convertible senior notes due 2031 and 2032, amendments to its revolving credit facility, entry into and completion of the Elektrofi acquisition, significant collaboration agreements, and executive appointments or transitions. These filings often include details on note terms, capped call transactions, credit covenants and merger conditions that are not fully described in press releases.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (not reproduced here but referenced in 8-Ks) typically contain broader discussions of Halozyme’s ENHANZE, Hypercon and MDASE technology portfolios, risk factors, royalty and collaboration structures, and overall financial condition. Investors use these filings to understand how platform licensing, proprietary products and acquisitions contribute to the company’s long-term strategy.
Stock Titan enhances this information with AI-powered summaries that highlight key terms in lengthy documents, such as conversion conditions for the company’s notes, leverage and coverage ratios in its credit agreement, and the main obligations and covenants in merger contracts. Users can also review disclosures related to executive compensation arrangements, transition agreements and other governance topics reported under Item 5.02 of Form 8-K.
By combining real-time updates from EDGAR with AI-generated explanations, the Halozyme filings page helps readers quickly locate and interpret the sections of 10-Ks, 10-Qs, 8-Ks and related exhibits that are most relevant to their analysis of HALO stock.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.
Halozyme Therapeutics insider Nicole LaBrosse executed option exercises and share sales under a Rule 10b5-1 plan on 09/10/2025. The reporting shows exercise of options to purchase 11,271 shares at $12.07 and 1,135 shares at $12.49, and brokered sales of 6,760 and 13,240 shares at weighted average prices in the $74.56–$76.30 range. After these transactions the reporting person beneficially owned 24,306 shares of common stock directly. The Form 4 discloses the trades were effected pursuant to a 10b5-1 trading plan adopted on June 11, 2025, and includes vesting histories for the reported options.
Form 144 notice filed for proposed sale of securities on NASDAQ totaling 22,227 shares with an aggregate market value of $1,690,807.89. The filing shows these shares represent part of the issuer's 116,966,000 outstanding shares and lists the approximate sale date as 09/10/2025.
The securities to be sold were acquired in two transactions: 12,406 shares from an option exercise on 09/10/2025 (paid in cash) and 9,821 shares as restricted stock units on 02/10/2023. The filer reports no sales of the issuer's securities in the past three months. Several standard filer and issuer identification fields in the notice are blank or not provided in the text.
Helen Torley, President and CEO and director of Halozyme Therapeutics (HALO), reported option exercises and share sales under a Rule 10b5-1 trading plan adopted March 21, 2025. She exercised multiple option blocks with an $8.11 exercise price on September 2-4, 2025, acquiring 60,000 shares from option exercises and receiving 60,000 option shares underlying those exercises. Concurrently she sold aggregated blocks of common stock on September 2-4, 2025 at weighted average prices reported in ranges between $71.99 and $75.44 per share. After these transactions, Ms. Torley beneficially owned 733,719 common shares and held remaining options exercisable into additional shares as reported.
Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported sales of common stock on 09/02/2025 executed under a pre-established Rule 10b5-1 trading plan adopted on 05/29/2025. The Form 4 shows three sell transactions: 100 shares at $71.71, 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38). After these disposals the reporting person beneficially owned 46,952 shares, held directly.
Halozyme Therapeutics (HALO) notice reports a proposed sale of 8,829 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 on the NASDAQ. The shares were originally acquired as Restricted Stock Units from the issuer on 04/30/2021. The filing shows an aggregate market value of $645,841.35 for the shares and lists 116,966,000 shares outstanding for the issuer. No other sales in the past three months are reported, and the filer affirms they are not aware of undisclosed material adverse information.
Helen Torley, President and CEO and a director of Halozyme Therapeutics (HALO), exercised a total of 60,000 stock options at an $8.11 exercise price and concurrently sold the resulting 60,000 common shares over three days. The sales were executed at weighted-average prices reported in ranges between $62.54 and $64.96 per share, and the Form reports 733,719 shares beneficially owned by the reporting person following these transactions.
The filings state the transactions were made under a written Rule 10b5-1 trading plan adopted March 21, 2025, and that the sold shares were acquired upon exercise of options with ten-year terms expiring in February 2026. The underlying options were originally granted February 3, 2016, with a four-year vesting schedule.